Poly-ADP-ribosylation in health and disease
- 1 April 2005
- journal article
- review article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 62 (7-8) , 739-750
- https://doi.org/10.1007/s00018-004-4505-1
Abstract
Poly(ADP-ribose) glycohydrolase (PARG) is a catabolic enzyme that cleaves ADP-ribose polymers formed by members of the PARP family of enzymes. Despite its discovery and subsequent partial purification in the 1970s [1–3] and the cloning of its single gene in the late 1990s [4], little is known about the role of PARG in cell function. Because of its low abundance within cells and its extreme sensitivity to proteases, PARG has been difficult to study. The existence of several PARG isoforms with different subcellular localizations is still debated today after more than 30 years of intensive research. In this article, we want to summarize and discuss the current knowledge related to PARG, its different forms and subcellular distribution. We also examine the possible biological roles of PARG in modulating chromatin structure, transcription, DNA repair and apoptosis.Keywords
This publication has 32 references indexed in Scilit:
- European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular riskEuropean Heart Journal, 2016
- 2016 European Guidelines on cardiovascular disease prevention in clinical practiceEuropean Heart Journal, 2016
- Cardiovascular disease in Europe — epidemiological update 2015European Heart Journal, 2015
- Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trialsPublished by Elsevier ,2015
- Targeting PCSK9 for HypercholesterolemiaAnnual Review of Pharmacology and Toxicology, 2014
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis SocietyEuropean Heart Journal, 2013
- Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel StatementCurrent Vascular Pharmacology, 2011
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)European Heart Journal, 2011
- A systematic review and meta-analysis on the therapeutic equivalence of statinsJournal of Clinical Pharmacy & Therapeutics, 2009
- Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000New England Journal of Medicine, 2007